Laurus labs Q1 FY24 earning summary
Poor results from laurus – Revenue down by 23%
EBITDA down by 63%, PAT down by 90% – 25 cr PAT this quater.
Heavy operational deleverage at play here 
API up 2% YoY, ARV stabilizing and good growth in oncology.
FDF down 18% YoY, CDMO down 57%.
Multi year deal with crop science leader in Q1,
Animal health commercial validation from Oct 2023
laurus bio 50 cr revenue in Q1, full utilization of R2 in FY25.
1000 cr capex in FY24. FY25 capex will be communicated in Q2
maintains FY24 will be consolidation, growth in FY25.
Disclosure:Invested
| Subscribe To Our Free Newsletter |
